Charles M. Winter net worth and biography

Charles Winter Biography and Net Worth

Insider of Janux Therapeutics

Charles is Chief Technical Officer at Janux, where he leads all aspects of process development and manufacturing from preclinical through commercialization. Charles brings to Janux more than 25 years of bioprocess experience for leading biotechnology and pharmaceutical companies and has played vital roles in bringing more than 20 molecules into clinical development and six to market, including Avastin^®, Herceptin^®, Rituxan^®, and Xolair^®. Charles started his career at Genentech where he spent 17 years in increasing roles of responsibility in bioprocess development and CMC leadership from preclinical through development and commercialization. After Genentech, he was Director of Biologics Development at Gilead, building biologics development and CMC platforms, capabilities and strategies. Charles then become Vice President of Manufacturing and Technology for JHL Biotech in Taiwan, running its cGMP contract manufacturing plant. Prior to joining Janux, Charles held senior leadership roles running outsourced CMC programs at Denali Therapeutics, Synthorx (now a Sanofi company), and AnaptysBio.

Charles received a B.S. in chemical engineering from the University of Wisconsin-Madison.

What is Charles M. Winter's net worth?: The estimated net worth of Charles M. Winter is at least $1.15 million as of January 2nd, 2026. Winter owns 77,721 shares of Janux Therapeutics stock worth more than $1,153,380 as of April 4th. This net worth approximation does not reflect any other assets that Winter may own. Learn More about Charles M. Winter's net worth.
How do I contact Charles M. Winter?: The corporate mailing address for Winter and other Janux Therapeutics executives is , , . Janux Therapeutics can also be reached via phone at 858-751-4493 and via email at [email protected]. Learn More on Charles M. Winter's contact information.
Has Charles M. Winter been buying or selling shares of Janux Therapeutics?: Charles M. Winter has not been actively trading shares of Janux Therapeutics within the last three months. Most recently, Charles M. Winter sold 2,401 shares of the business's stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a transaction totalling $32,965.73. Following the completion of the sale, the insider now directly owns 77,721 shares of the company's stock, valued at $1,067,109.33. Learn More on Charles M. Winter's trading history.
Who are Janux Therapeutics' active insiders?: Janux Therapeutics' insider roster includes David Campbell (Founder, President & CEO), Thomas Diraimondo (Insider), Maria Dobek (VP), Zachariah Mciver (Insider), Andrew Meyer (Chief Business Officer), and Charles Winter (Insider). Learn More on Janux Therapeutics' active insiders.
Are insiders buying or selling shares of Janux Therapeutics?: During the last year, insiders at the sold shares 11 times. They sold a total of 49,031 shares worth more than $1,178,961.32. The most recent insider tranaction occured on January, 2nd when insider Thomas Diraimondo sold 2,505 shares worth more than $34,393.65. Insiders at Janux Therapeutics own 8.1% of the company. Learn More about insider trades at Janux Therapeutics.
Information on this page was last updated on 1/2/2026.

Charles M. Winter Insider Trading History at Janux Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/2/2026	Sell	2,401	$13.73	$32,965.73	77,721

Charles M. Winter Buying and Selling Activity at Janux Therapeutics

Janux Therapeutics Company Overview

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Today's Range

Now: $14.84

$14.22

$14.91

50 Day Range

MA: $13.70

$12.18

$14.84

2 Week Range

Now: $14.84

$12.12

$35.34

Volume

1,305,005 shs

Average Volume

1,217,380 shs

Market Capitalization

$902.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.82